| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers S > Headlines for Sangamo Biosciences Inc. > News item |
Sangamo says it will take diabetic neuropathy program into phase 2 clinical trials this year
By Jennifer Lanning Drey
Eugene, Ore., June 28 - Sangamo BioSciences, Inc. plans to move its lead diabetic neuropathy program into phase 2 clinical trials in the second half of the year, said Edward Lanphier, president and chief executive officer of Sangamo, at the Jefferies Life Sciences Conference on Wednesday.
Sangamo is developing SB-509 for the treatment of diabetic neuropathy. SB-509 is a formulation of a zinc finger DNA-binding protein transcription factor (ZFP TF), designed to up-regulate the expression of the gene encoding vascular endothelial growth factor.
Currently, diabetic neuropathy is treated with painkillers or antidepressants, Lanphier said.
"There's nothing out there that really is intended to stop or even reverse this loss of nerves in diabetics," he said.
The company currently has an ongoing phase 1b clinical trial for SB-509, which it expects to finish in the third quarter, Lanphier said.
In mid-June, researchers reported positive findings from Sangamo's phase 1a and 1b clinical trial in subjects with diabetic neuropathy, which demonstrated that a single treatment of SB-509 was well tolerated and that no severe adverse events were observed.
Additional phase 1 trials
Sangamo also Wednesday that it plans to start or complete at least three phase 1 clinical trials before the end of the year.
In particular, the company hopes to begin clinical trials to study the use of ZFP-based therapeutics for HIV patients, Lanphier said.
Sangamo BioSciences is a Richmond, Calif., company that researches and develops DNA-binding proteins for therapeutic gene regulation and modification.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.